Target intelligence / Profile preview

Integrin subunit alpha L (ITGAL)

Target
ITGAL
Molecular classification
Receptor, Cell adhesion molecule, Integrin family
01

Overview

Integrin subunit alpha L (ITGAL), also known as CD11A, forms a heterodimeric complex with the beta-2 integrin (CD18/ITGB2) to make lymphocyte function-associated antigen 1 (LFA-1), a critical leukocyte cell surface receptor. LFA-1 mediates firm adhesion between leukocytes and other cells via binding to intercellular adhesion molecules (ICAM-1, -2, -3, -4) and is essential for immune cell trafficking, activation, cytotoxic function, and migration across the endothelium. Its central role in immune cell recruitment and activation underpins its function in inflammatory responses, host defense, and tumor immune surveillance. Altered expression and function of ITGAL are implicated in diseases such as autoimmune disorders, cancer, chronic inflammation, and immunodeficiency[1][2][3].

Other names
Integrin alpha-LCD11ALFA-1ALFA-1LFA1ACD11 antigen-like family member ALeukocyte adhesion glycoprotein LFA-1 alpha chainLeukocyte function-associated molecule 1 alpha chainLymphocyte function-associated antigen 1 alpha polypeptideAntigen CD11A (p180)
02

Mechanism of action

Inhibition of leukocyte adhesion and migration by blocking LFA-1/ICAM interaction Modulation of immune cell activation and infiltration

03

Biological functions

Immune responseCell adhesionLymphocyte costimulatory signalingLeukocyte transmigration
04

Disease associations

InflammationCancerInfectionCongenital neutropenia
05

Safety considerations

Increased risk of infections due to immunosuppressionPotential for immune dysregulation and reactivation of latent infectionsEfalizumab was withdrawn due to risk of progressive multifocal leukoencephalopathy (PML)
06

Interacting drugs

Efalizumab (withdrawn anti-LFA-1 monoclonal antibody)

1 more in the full profile.

07

Biomarkers

ITGAL expression as a prognostic biomarker in gastric cancer and potentially other cancersAssociated with degree of tumor-infiltrating immune cellsCo-expression with immune exhaustion markers (e.g., PD1/PDCD1)

Beyond the preview

Go deeper on Integrin subunit alpha L (ITGAL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Integrin subunit alpha L (ITGAL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call